You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial

Article metrics

Article menu

Download PDFPDF

XML
Interstitial lung disease
Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial

 

Online download statistics by month:

Online download statistics by month: August 2018 to March 2024

AbstractFullPdf
Aug 201813113050
Sep 2018233230110
Oct 201813213250
Nov 201812211851
Dec 2018555538
Jan 2019545330
Feb 2019818040
Mar 2019585548
Apr 2019575446
May 20191019250
Jun 2019565333
Jul 2019655942
Aug 2019535140
Sep 2019696736
Oct 2019727233
Nov 2019474426
Dec 2019524731
Jan 2020625931
Feb 2020444322
Mar 2020656026
Apr 2020575030
May 2020464531
Jun 2020403812
Jul 2020393713
Aug 202033289
Sep 2020787325
Oct 2020736643
Nov 2020383611
Dec 2020363410
Jan 2021464518
Feb 2021343013
Mar 2021454314
Apr 2021484515
May 2021383520
Jun 202130298
Jul 2021333217
Aug 2021262417
Sep 2021212115
Oct 2021333031
Nov 2021201823
Dec 202119179
Jan 2022222213
Feb 2022191911
Mar 2022201813
Apr 2022969213
May 2022434319
Jun 2022383612
Jul 202224252
Aug 2022453911
Sep 2022473222
Oct 202227279
Nov 202237359
Dec 2022252719
Jan 202320204
Feb 202340386
Mar 2023272817
Apr 2023191511
May 2023272414
Jun 202324243
Jul 202317146
Aug 202321218
Sep 202313124
Oct 202327255
Nov 202336368
Dec 20231088311
Jan 20247670135
Feb 2024322415
Mar 2024313216
Total340332111633